WO2011085288A3 - Method of administration and treatment - Google Patents

Method of administration and treatment Download PDF

Info

Publication number
WO2011085288A3
WO2011085288A3 PCT/US2011/020634 US2011020634W WO2011085288A3 WO 2011085288 A3 WO2011085288 A3 WO 2011085288A3 US 2011020634 W US2011020634 W US 2011020634W WO 2011085288 A3 WO2011085288 A3 WO 2011085288A3
Authority
WO
WIPO (PCT)
Prior art keywords
administration
treatment
methods
patients
age
Prior art date
Application number
PCT/US2011/020634
Other languages
French (fr)
Other versions
WO2011085288A2 (en
Inventor
Chun-Fang Xu
Howard Ashley Ball
Original Assignee
Glaxo Wellcome Manufacturing Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Manufacturing Pte Ltd filed Critical Glaxo Wellcome Manufacturing Pte Ltd
Publication of WO2011085288A2 publication Critical patent/WO2011085288A2/en
Publication of WO2011085288A3 publication Critical patent/WO2011085288A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is directed to methods of administering VEGF or VEGFR inhibitors as well as methods of treating cancer and age-related macular degeneration in patients in need thereof.
PCT/US2011/020634 2010-01-11 2011-01-10 Method of administration and treatment WO2011085288A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29393710P 2010-01-11 2010-01-11
US61/293,937 2010-01-11
US37127810P 2010-08-06 2010-08-06
US61/371,278 2010-08-06
US38887110P 2010-10-01 2010-10-01
US61/388,871 2010-10-01

Publications (2)

Publication Number Publication Date
WO2011085288A2 WO2011085288A2 (en) 2011-07-14
WO2011085288A3 true WO2011085288A3 (en) 2011-10-06

Family

ID=44306182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/020634 WO2011085288A2 (en) 2010-01-11 2011-01-10 Method of administration and treatment

Country Status (1)

Country Link
WO (1) WO2011085288A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207486A1 (en) * 2006-03-03 2007-09-06 University Of Southern California Angiogenesis pathway gene polymorphisms for therapy selection
US20090306625A1 (en) * 2007-03-09 2009-12-10 Angiodynamics, Inc. Treatment systems and methods for renal-related diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207486A1 (en) * 2006-03-03 2007-09-06 University Of Southern California Angiogenesis pathway gene polymorphisms for therapy selection
US20090306625A1 (en) * 2007-03-09 2009-12-10 Angiodynamics, Inc. Treatment systems and methods for renal-related diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HACKING ET AL.: "Increased in vivo transcription of an IL-8 haplotype associated with respiratory synctial virus disease-susceptibility.", GENES AND IMMUNITY, vol. 5, 2004, pages 274 - 282 *

Also Published As

Publication number Publication date
WO2011085288A2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
EA201590870A1 (en) AMINO-SUBSTITUTED IMIDAZO [1,2-a] Pyridinecarboxamides and their use
EP4140487A8 (en) Combination therapy for treating cancer
WO2014031487A8 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
WO2014062720A3 (en) Methods of treating cancer
WO2012062925A3 (en) Compounds and methods for treating pain
MX343706B (en) Novel heterocyclic derivatives.
MX2014005928A (en) Heterocyclic inhibitors of glutaminase.
MX2016007351A (en) Combination therapy for treating cancer.
MY169987A (en) Selective pi3k delta inhibitors
UA114476C2 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
IN2015DN00450A (en)
IN2015DN01151A (en)
EA201600096A1 (en) BENZYL-1H-PYRAZOL [3,4-B] Pyridine and their use
IL254446A0 (en) Implantable drug delivery compositions and methods of treatment thereof
EA201492279A1 (en) Drug for the prevention and / or treatment of polycystic kidney disease
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
EA201491500A1 (en) FIBROZA TREATMENT METHODS
EA201290603A1 (en) METHOD OF TREATMENT
EA201491427A1 (en) SUBSTITUTED PHENYLIMIDAZOPIRAZOLES AND THEIR APPLICATION
AU2013357030A8 (en) Chlorin derivative useful in photodynamic therapy and diagnosis
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
MX2015005111A (en) Herbal composition for the prevention and treatment of tnf-î± mediated diseases.
IN2014DN09437A (en)
WO2011153243A3 (en) Anti-angiogenesis therapy for treating gastric cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11732263

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11732263

Country of ref document: EP

Kind code of ref document: A2